Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million May 6, 2026 View Press Release
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock May 5, 2026 View Press Release
Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress May 5, 2026 View Press Release
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease May 5, 2026 View Press Release
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease March 30, 2026 View Press Release
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results February 26, 2026 View Press Release
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 8, 2026 View Press Release
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease December 22, 2025 View Press Release
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 5, 2025 View Press Release